MolNFT v1 · #169861 · protein
Scoe with oxovanadium and the caba substrate bound and HIS299 and ARG157 flipped out
6XPA · Scoe protein: “Scoe with oxovanadium and the caba substrate bound and HIS299 and ARG157 flipped out”. X-ray diffraction, 3 ligands (7UC, VVO, CL), 1 pocket (best druggability 0.83). MolNFT v1 #169861 on GenesisL1: 3D structure…
- PDB
- 6XPA
- Type
- protein
- Length
- 296 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Scoe protein
- UniProt
- A0A3B6UEU3
- Ligands
- 7UC, VVO, CL
- Pockets
- 1 · best druggability 0.83
Structure
x-ray diffraction · 1 distinct chain · 22% helix, 26% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Scoe protein | protein | 296 | 22% helix, 26% strand | A0A3B6UEU3 |
Ligands and binding sites
- 7UC · (3~{R})-3-(2-hydroxy-2-oxoethylamino)butanoic acid · ligand · chains A
- VVO · oxovanadium(2+) · ligand · chains A
- CL · Chloride ion · ion · 2 copies · chains A
- ACT · Acetate ion · additive · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 317 | 0.83 | 0.93 | 53 | 7UC, VVO |
Compared structures
- 6XPA · ScoE with oxovanadium and the CABA substrate bound and His299 and Arg157 flipped out · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt A0A3B6UEU3
- Elsewhere: RCSB PDB 6XPA · PDBe 6XPA · UniProt A0A3B6UEU3
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.